A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Completed · Phase 2 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus

In brief

The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.

Key facts

Study ID
NCT06143046
Run by
ModernaTX, Inc.
People needed
360
Starts
2023-11-15
Expected to finish
2026-05-25
Last updated by the study team
2026-06-10

Who can join

Age: any, up to 40. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.